|Bid||7.55 x 2900|
|Ask||0.00 x 40700|
|Day's Range||8.00 - 8.49|
|52 Week Range||6.22 - 14.65|
|Beta (3Y Monthly)||2.57|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.50|
Spectrum Pharmaceuticals (SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at the Jefferies 2019 London Healthcare Conference being held in London. A live webcast of Spectrum's presentation will be available at http://www.sppirx.com. Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies.
Spectrum Pharmaceuticals , a biopharmaceutical company focused on novel and targeted oncology therapies, announced today it will host a conference call with management to discuss the third quarter 2019 financial results, provide an update on the company's business, and discuss expectations for the future on Thursday, November 7, 2019 at 4:30 p.m.
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with a primary focus in hematology and oncology, announced today that the company submitted an updated Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ROLONTIS (eflapegrastim). The BLA for ROLONTIS is supported by data from two identically designed Phase 3 clinical trials, ADVANCE and RECOVER, which evaluated the safety and efficacy of ROLONTIS in 643 early-stage breast cancer patients for the treatment of neutropenia due to myelosuppressive chemotherapy. In both studies, ROLONTIS demonstrated the pre-specified hypothesis of non-inferiority (NI) in Duration of Severe Neutropenia (DSN) and a similar safety profile to pegfilgrastim.
Investors need to pay close attention to Spectrum Pharma (SPPI) stock based on the movements in the options market lately.
Spectrum Pharmaceuticals, Inc. (SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today a publication from The University of Texas, MD Anderson Cancer Center entitled, “Pan-Cancer Landscape and Functional Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.” The publication appears in the Oct 3, 2019 online issue at https://www.cell.com/cancer-cell/fulltext/S1535-6108(19)30384-8 and will be published in a future print issue of Cancer Cell. “Our analysis is the largest ever conducted to understand the diversity of HER2 mutations across 25 cancer types, including more than 200,000 patients from cBioPortal, MD Anderson, Foundation Medicine, and Guardant Health,” said John Heymach, M.D., Ph.D., Chairman and Professor, Department of Thoracic/Head and Neck Medical Oncology at MD Anderson.
We can readily understand why investors are attracted to unprofitable companies. For example, although...
FibroGen (FGEN) doses the first patient in a phase II study on roxadustat for the treatment of anemia in cancer patients receiving chemotherapy.
FibroGen's (FGEN) Evrenzo (roxadustat) wins a marketing approval in Japan for treating anemia caused by chronic kidney disease in dialysis-dependent patients.
Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 28.13% and -349.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Spectrum Pharma (SPPI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.